-
Pramac Yamaha replace Miller with Guevara for 2027 MotoGP season
-
New Zealand make three changes for second South Africa Test
-
Bouaddi needs time at Man City despite 100m euro fee, says Maresca
-
Stocktwits Expands CME Group Alliance with the Integration of Single Stock Futures Data
-
MEXC Launches SHEIN Subscription with $1M Quota as Inaugural IPO Express Event
-
'Mature' Colapinto extends contact with Alpine through 2027
-
Iran, Qatar hold Hormuz talks as US blockade chokes Iran oil imports
-
Atletico rule out any talks with Barcelona over Alvarez
-
Defiant Dinusha helps Sri Lanka draw second India Test
-
Tech stocks lifted by Nvidia as broader markets struggle
-
Pakistan bowl against England in rain-delayed second Test
-
Delap joins Nottingham Forest in club-record deal
-
Barcola move from PSG to Liverpool 'on track': source
-
ICC President Akane Warns U.S. Sanctions Threaten Court's Future
-
Swallowed by silt: Survivors recount Nepal flood horror
-
Delays in Cancer Radiotherapy and Surgery Target Times
-
Germany's Merz hosts 'frugal' leaders ahead of EU budget battle
-
Acrid stench, charred walls reveal devastation of Pakistan infant ward fire
-
Barca sign Croatia goalkeeper Livakovic
-
Norway holds its breath as King Harald's health deteriorates
-
Rain delays England's bid to put off-field incidents behind them
-
Germany reports record 15,800 heat-related deaths this summer
-
World record holder Sawe withdraws from Berlin Marathon
-
YouTuber Chris Sails Arrested for Allegedly Falsifying Emergency Report
-
Driven by faith, activists stand up to fellow Jews to protect Palestinians
-
Dinusha defiant as Sri Lanka lead by 170 in India Test
-
Therapy Culture Performance: How the Lindsay Clancy Trial Sparked a Trend of Viral Maternal Distress
-
Taiwan lawmakers approve $7.6 bn drone budget as China threat grows
-
Norway's King Harald, 89, in 'extremely serious' condition
-
TechCentral.ie Daily Briefing: Agentic AI Firm Doubles Headcount to 60
-
How a glacier collapse may have caused Nepal-Tibet disaster
-
KiiChain Integrates TRON to Expand 24/7 On-Chain FX and Stablecoin Payments
-
Harmovest Capital Strengthens Global Financial Services Through Technology and Compliance
-
Japan to survey animal cafes over hygiene, welfare concerns
-
Nvidia to buy AI platform Hugging Face for $12.9 bn: report
-
Desperate families search for missing after Nepal floods
-
Palace intrigue in Uganda as succession battle heats up
-
The missing in Nepal-Tibet flash floods
-
'Housing First' approach gets Swedish city's homeless off streets
-
Search for 1,300 missing after deadly Nepal-Tibet floods
-
Czech duo Muchova and Mensik win US Open mixed doubles title
-
Once a top export, prized Kashmir carpet fades
-
Japan's 'polka dot queen' artist Yayoi Kusama dies aged 97
-
Search for 1,000 missing after deadly Nepal-Tibet floods
-
Nepal-Tibet disaster: what we know
-
Park So-yeon first woman to play for eSports powerhouse South Korea
-
China deploys record number of ships around Taiwan as pressure grows
-
Yayoi Kusama: Japan's kaleidoscopic, troubled 'polka dot queen'
-
Ruthless Bayern target treble as rivals reboot on Bundesliga return
-
Euro champ Hunt 'on her toes' against world's best in Zurich 100m
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion.
RedChip began introducing Cidara to its global microcap and small-cap investor network in 2021, when the company's market capitalization was under $100 million and its groundbreaking antiviral and antifungal programs were still largely undiscovered by the broader investment community.
"Cidara's journey from a sub-$100 million emerging growth story to a multibillion-dollar strategic acquisition by Merck is exactly the type of transformational outcome RedChip seeks to spotlight for investors," said Dave Gentry, CEO of RedChip Companies. "We were proud to share the Cidara story at a time when its innovative Cloudbreak® platform and long-acting antiviral programs were just beginning to attract institutional attention. Seeing that early science culminate in one of the largest biotech acquisitions of the year validates both Cidara's vision and the importance of bringing promising small-cap opportunities to investors early."
As detailed in Merck's announcement, the acquisition centers on CD388, Cidara's investigational long-acting, strain-agnostic antiviral designed to prevent influenza infection in individuals at high risk of complications. CD388, now in Phase 3 development, was granted Breakthrough Therapy Designation by the FDA and is viewed as a potentially first-in-class seasonal prevention solution with global commercial potential.
"Cidara exemplifies the type of emerging blue-chip story that aligns with RedChip's 33-year mission," Gentry added. "We congratulate the Cidara team on this extraordinary milestone and look forward to continuing our work discovering tomorrow's leading innovators today."
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]
--END--
SOURCE: RedChip Companies, Inc.
View the original press release on ACCESS Newswire
F.Ramirez--AT